FUNDING
Key Metrics
Total funding
$272M
As of Jul 31, 2026Value Add Pulse research
Company Snapshot
Triveni Bio is a Biotech company, based in Waltham, Massachusetts, founded 2023. Total funding $272M (As of Jul 31, 2026).
Recent changes
- Jul 31, 2026Jul 31, 2026First reported total funding: $272M Value Add Pulse enrichment
- Jun 18, 2026Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in Immunology Pulse story
- Jun 17, 2026Jun 17, 2026Raised $65M Series C Triveni Bio
- Jun 17, 2026Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2026 | Series C | $65M | — | Triveni Bio |
Investors
Latest Pulse
- Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in ImmunologyTriveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.→
- Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology TherapeuticsTriveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.→
Coverage Timeline
newest firstAll Coverage
FUNDING$65M
Triveni Bio Raises $65M for Antibody Therapeutics in Immunology
Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.
FUNDING
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
FUNDING$65M
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.
Related Companies
Sources & methodologyshow
Where these figures come from
- Triveni Bioprimary source1 fact
- Value Add Pulse researchValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.